Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations

Huntington Beach, California and Amsterdam (ots/PRNewswire) -

- International Expert Panel Recommends Use of Multigene
Profiling Assays and Finds Intermediate Scores Lack Clinical Utility

Agendia, a world leader in molecular cancer diagnostics, today
announced the inclusion of its breast cancer recurrence test
MammaPrint in St. Gallen's 2009 International Expert Consensus on the
primary therapy of early breast cancer. The recommendations have been
published online in the Annals of Oncology and will appear in the
August print edition.

The St. Gallen expert panel consists of key opinion leaders from
across Europe (53%), the United States (33%), and rest of the world
(14%). In the recently published article highlighting the 2009
recommendations, the panellists emphasize that "in an important
change from the previous St. Gallen conference...the Panel supported
the use of a validated multigene- profiling assay, if readily
available, as an adjunct to high-quality phenotyping of breast cancer
in cases in which the indication for adjuvant chemotherapy remained
uncertain."

In addition, the panel cautioned that so-called intermediate
scores are not useful in clinical decision making. Currently,
MammaPrint is the only breast cancer recurrence assay available that
accurately yields a binary result, without an intermediate group,
addressing the panel's recommendations. The FDA-cleared assay is
always clinically useful and indicates whether a patient is at low or
high risk for metastasis and the resulting clarity is vital in
helping physicians personalize treatment options.

"St. Gallen's guideline inclusion is a key step in further
establishing MammaPrint as a standard of care. It also supports our
commitment to upholding rigorous standards of quality and efficacy,"
said Dr. Bernhard Sixt, Agendia's President and Chief Executive
Officer. "With MammaPrint we aim to provide breast cancer patients
and their physicians with definitive answers to crucial treatment
questions."

In addition to MammaPrint, the company also offers TargetPrint to
further improve breast cancer treatment options. TargetPrint
quantitatively determines the gene expression levels of HER2neu,
estrogen and progesterone receptors. Ongoing research and development
efforts continue to augment Agendia's ability to accurately predict
breast cancer recurrence, and help physicians tailor individual
treatment plans to their patients.

For online access to the Annals of Oncology:
http://annonc.oxfordjournals.org/cgi/content/full/mdp322v1

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatment within reach of patients. Building on a cutting edge
genomics platform for tumor gene expression profiling, the company's
tests aim to help physicians more accurately tailor cancer therapy.
The company markets four products, with several new genomic tests in
development. Agendia collaborates with pharmaceutical companies in
the development of highly effective personalized drugs in the area of
oncology and was awarded the 2008 North American Oncology Clinical
Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia
is based in Huntington Beach, California, and in Amsterdam, The
Netherlands. For more information please visit
http://www.agendia.com.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media contacts: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
hans.herklots@agendia.com. Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, vdelva@ricochetpr.com